PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

BACKGROUND: Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is the most frequent subtype of secondary HLH triggered by infections. Previous studies have shown that ~30 % or more of patients with EBV-HLH do not respond to standard therapy. This study investigated the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jingshi, Wang, Yini, Wu, Lin, Zhang, Jia, Lai, Wenyuan, Wang, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017041/
https://www.ncbi.nlm.nih.gov/pubmed/27613189
http://dx.doi.org/10.1186/s13045-016-0317-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017041/
https://www.ncbi.nlm.nih.gov/pubmed/27613189
http://dx.doi.org/10.1186/s13045-016-0317-7

Ejemplares similares